Clarius Group LLC trimmed its position in shares of Sage Therapeutics, Inc. (NASDAQ:SAGE) by 13.4% in the 3rd quarter, according to the company in its most recent filing with the Securities and Exchange Commission (SEC). The institutional investor owned 129,068 shares of the biopharmaceutical company’s stock after selling 20,000 shares during the quarter. Sage Therapeutics makes up about 3.4% of Clarius Group LLC’s portfolio, making the stock its 4th biggest holding. Clarius Group LLC owned 0.34% of Sage Therapeutics worth $8,041,000 at the end of the most recent reporting period.

Other large investors have also recently bought and sold shares of the company. Bank of New York Mellon Corp increased its holdings in Sage Therapeutics by 36.5% in the 3rd quarter. Bank of New York Mellon Corp now owns 2,710,027 shares of the biopharmaceutical company’s stock worth $168,834,000 after acquiring an additional 724,494 shares in the last quarter. BlackRock Inc. increased its holdings in Sage Therapeutics by 5.9% in the 2nd quarter. BlackRock Inc. now owns 3,031,548 shares of the biopharmaceutical company’s stock worth $241,431,000 after acquiring an additional 168,424 shares in the last quarter. New York State Common Retirement Fund increased its holdings in Sage Therapeutics by 258.0% in the 3rd quarter. New York State Common Retirement Fund now owns 149,564 shares of the biopharmaceutical company’s stock worth $9,318,000 after acquiring an additional 107,782 shares in the last quarter. Farallon Capital Management LLC purchased a new stake in Sage Therapeutics in the 2nd quarter worth $7,964,000. Finally, Pioneer Investment Management Inc. increased its holdings in Sage Therapeutics by 126.9% in the 2nd quarter. Pioneer Investment Management Inc. now owns 158,418 shares of the biopharmaceutical company’s stock worth $12,616,000 after acquiring an additional 88,585 shares in the last quarter.

Shares of Sage Therapeutics, Inc. (NASDAQ:SAGE) traded down $2.78 on Thursday, reaching $85.47. 3,025,900 shares of the company’s stock traded hands, compared to its average volume of 543,285. Sage Therapeutics, Inc. has a 52 week low of $44.55 and a 52 week high of $99.80.

Sage Therapeutics (NASDAQ:SAGE) last announced its earnings results on Thursday, November 2nd. The biopharmaceutical company reported ($1.97) earnings per share (EPS) for the quarter, topping the consensus estimate of ($1.98) by $0.01. The business’s quarterly revenue was up .0% on a year-over-year basis. sell-side analysts forecast that Sage Therapeutics, Inc. will post -7.36 earnings per share for the current year.

TRADEMARK VIOLATION WARNING: This report was originally posted by The Cerbat Gem and is the property of of The Cerbat Gem. If you are accessing this report on another publication, it was stolen and republished in violation of US & international copyright laws. The legal version of this report can be read at https://www.thecerbatgem.com/2017/11/16/sage-therapeutics-inc-sage-stake-decreased-by-clarius-group-llc.html.

SAGE has been the subject of several recent analyst reports. Royal Bank Of Canada boosted their price target on shares of Sage Therapeutics from $117.00 to $120.00 in a report on Thursday, November 2nd. SunTrust Banks, Inc. reissued a “buy” rating and issued a $82.00 price target (down previously from $95.00) on shares of Sage Therapeutics in a report on Wednesday, September 13th. Canaccord Genuity cut their price target on shares of Sage Therapeutics from $110.00 to $81.00 and set a “buy” rating for the company in a report on Tuesday, September 12th. Stifel Nicolaus initiated coverage on shares of Sage Therapeutics in a report on Wednesday, August 9th. They issued a “buy” rating and a $104.00 price target for the company. Finally, Cowen and Company reissued a “buy” rating and issued a $100.00 price target on shares of Sage Therapeutics in a report on Friday, August 4th. Three equities research analysts have rated the stock with a hold rating, thirteen have issued a buy rating and one has assigned a strong buy rating to the company’s stock. The stock presently has an average rating of “Buy” and an average price target of $103.43.

About Sage Therapeutics

SAGE Therapeutics, Inc is a clinical-stage biopharmaceutical company. The Company is engaged in developing and commercializing medicines to treat central nervous system (CNS) disorders. The Company’s lead product candidate, SAGE-547 is an intravenous formulation of allopregnanolone, a neurosteroid that acts as a synaptic and extrasynaptic modulator of the Gamma-Amino Butyric Acid-A (GABAA) receptor.

Want to see what other hedge funds are holding SAGE? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Sage Therapeutics, Inc. (NASDAQ:SAGE).

Institutional Ownership by Quarter for Sage Therapeutics (NASDAQ:SAGE)

Receive News & Stock Ratings for Sage Therapeutics Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Sage Therapeutics Inc. and related stocks with our FREE daily email newsletter.